Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medigene

- PMLiVE

Pfizer and Roivant form new company to develop inflammatory disease drug

RVT-3101 is currently being evaluated in a global phase 2b study for ulcerative colitis

- PMLiVE

Europe urged to adapt faster to gene therapy challenges

Resistance to high prices, even with novel payment models

- PMLiVE

Amicus forms gene therapy manufacturing partnership with Catalent

Biotech invests to speed gene therapies into clinical trials

- PMLiVE

Syncona start-up Quell Therapeutics appoints chief exec

Biotech focusing on Tregs

- PMLiVE

Sanofi exiting Voyager gene therapy pact is ‘surprising’, says analyst

Move cuts pipeline depth, says GlobalData

- PMLiVE

Oxford Biomedica gets £53m cash injection from Novo venture arm

Cell and gene therapy specialist needs to invest to stay ahead

- PMLiVE

Novartis secures US approval – and payers’ blessing – for $2m gene therapy Zolgensma

Novel financing deal could be sector's future

- PMLiVE

Health comms agency emotive hires new cell and gene therapy leader

New division will cater to fast-expanding field

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Syncona launches another cell therapy company, Treg specialist Quell

Focuses on novel immune system approach

- PMLiVE

Bluebird and Alexion veterans launch cell and gene venture ElevateBio

'Basecamp' will provide expertise and labs to launch multiple firms

- PMLiVE

Gilead unveils plan to separate Kite cell therapy unit

Comes as Yescarta misses analyst expectations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links